Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010
- PMID: 24300242
- PMCID: PMC4697444
- DOI: 10.1161/CIRCHEARTFAILURE.113.000784
Emergency department visits and hospitalizations for digoxin toxicity: United States, 2005 to 2010
Abstract
Background: Recent data on digoxin prescribing and adverse events are lacking but could help inform the management of digoxin in contemporary heart failure treatment.
Methods and results: We determined nationally representative numbers and rates of emergency department (ED) visits for digoxin toxicity in the United States using 2005 to 2010 reports from the National Electronic Injury Surveillance System-Cooperative Adverse Drug Event Surveillance project and the National Ambulatory (and Hospital Ambulatory) Medical Care Surveys. Based on 441 cases, an estimated 5156 (95% confidence interval [CI], 2663-7648) ED visits for digoxin toxicity occurred annually in the United States; more than three fourths (78.8% [95% CI, 73.5%-84.1%]) resulted in hospitalization. Serum digoxin level was ≥2.0 ng/mL for 95.8% (95% CI, 93.2%-98.4%) of estimated ED visits with levels reported (n=251 cases). The rate of ED visits per 10 000 outpatient prescription visits among patients≥85 years was twice that of patients 40 to 84 years (rate ratio, 2.4 [95% CI, 1.2-5.0]); among women, the rate was twice that of men (rate ratio, 2.3 [95% CI, 1.1-4.7]). Digoxin toxicity accounted for an estimated 1.0% (95% CI, 0.6%-1.4%) of ED visits for all adverse drug events among patients≥40 years, but an estimated 3.3% (95% CI, 2.3%-4.4%) of ED visits and 5.9% (95% CI, 4.0%-7.9%) of hospitalizations for all adverse drug events among patients≥85 years. Estimated annual ED visits and hospitalizations remained relatively constant from 2005 to 2010.
Conclusions: Digoxin toxicity is not declining; more careful prescribing to high-risk groups and improved monitoring of serum levels might be needed to reduce morbidity from outpatient digoxin use.
Keywords: digoxin; drug-related side effects and adverse reactions; emergency service, hospital; heart failure; hospitalization.
References
-
- HCUPnet. Healthcare Cost and Utilization Product (HCUP) Agency for Healthcare Research and Quality; 2010. [Accessed August 27, 2013]. Available at: http://hcupnet.ahrq.gov.
-
- Centers for Medicare and Medicaid Services. [Accessed August 27, 2013];Medicare program; hospital inpatient prospective payment systems for acute care hospitals and the long-term care hospital prospective payment system and fiscal year 2013 rates; hospitals’ resident caps for graduate medical education payment purposes; quality reporting requirements for specific providers and for ambulatory surgical centers. Available at: https://www.federalregister.gov/articles/2012/08/31/2012-19079/medicare-.... - PubMed
-
- Fiegl C. 2,200 hospitals face Medicare pay penalty for readmissions. American Medical News; [Accessed August 27, 2013]. Available at: http://www.ama-assn.org/amednews/2012/08/27/gvsb0827.htm.
-
- Gheorghiade M, Harinstein ME, Filippatos GS. Digoxin for the treatment of chronic and acute heart failure syndromes. Acute Card Care. 2009;11:83–87. - PubMed
-
- Abraham WT, Adamson PB, Bourge RC, Aaron MF, Costanzo MR, Stevenson LW, Strickland W, Neelagaru S, Raval N, Krueger S, Weiner S, Shavelle D, Jeffries B, Yadav JS CHAMPION Trial Study Group. Wireless pulmonary artery haemodynamic monitoring in chronic heart failure: a randomized controlled trial. Lancet. 2011;377:658–666. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical